Bloodstream Infection Caused by S. Aureus in Patients with Cancer: a 10-year Longitudinal Single-center Study
Overview
Oncology
Authors
Affiliations
Background: Staphylococcus aureus bloodstream infections (SABIs) represent a significant cause of morbidity and mortality in cancer patients. In this study, we compared infection characteristics and evaluated epidemiology and risk factors associated to SABIs and 30-day attributable mortality in cancer patients.
Methods: Clinical and microbiological data from patients with cancer and positive blood cultures for S. aureus were retrieved during a 10-year period at an oncology reference center. Analyses were performed according to type of malignancy and infection with methicillin-resistant S. aureus (MRSA). Data was evaluated using competing risk analyses to identify risk factors associated to 30-day mortality and used to create a point system for mortality risk stratification.
Results: We included 450 patients and MRSA was documented in 21.1%. Hospital-acquired infection, healthcare-associated pneumonia, and type-2 diabetes were associated to MRSA. In patients with hematologic malignancies, MRSA was more frequent if hospital-acquired, but less likely in primary bacteremia. Variables associated to mortality included abdominal source of infection, hematologic malignancy, MRSA, glucose levels > 140 mg/dL, and infectious endocarditis; catheter removal and initiation of adequate treatment within 48 h of positive blood culture were protective factors. From our designed mortality prediction scale, patients with a score > 3 had a 70.23% (95%CI 47.2-85.3%) probability of infection-related death at 30 days.
Conclusion: SABIs are a significant health burden for cancer patients. Risk factors for SABI-related mortality in this population are varied and impose a challenge for management to improve patient's outcomes. Risk stratification might be useful to evaluate 30-day mortality risk.
Ciapponi A, Bardach A, Sandoval M, Palermo M, Navarro E, Espinal C Emerg Infect Dis. 2023; 29(11):2335-2344.
PMID: 37877573 PMC: 10617342. DOI: 10.3201/eid2911.230753.
Danielsen A, Franconeri L, Page S, Myhre A, Tornes R, Kacelnik O BMC Infect Dis. 2023; 23(1):247.
PMID: 37072711 PMC: 10114324. DOI: 10.1186/s12879-023-08182-3.
Pasman R, Krom B, Zaat S, Brul S Front Oral Health. 2022; 3:851786.
PMID: 35464779 PMC: 9021398. DOI: 10.3389/froh.2022.851786.
Abdel-Shafi S, El-Serwy H, El-Zawahry Y, Zaki M, Sitohy B, Sitohy M Antibiotics (Basel). 2022; 11(3).
PMID: 35326851 PMC: 8944761. DOI: 10.3390/antibiotics11030389.
Wojcik-Bojek U, Rozalska B, Sadowska B Int J Mol Sci. 2022; 23(2).
PMID: 35055134 PMC: 8781139. DOI: 10.3390/ijms23020948.